JP2022529996A5 - - Google Patents
Info
- Publication number
- JP2022529996A5 JP2022529996A5 JP2021562350A JP2021562350A JP2022529996A5 JP 2022529996 A5 JP2022529996 A5 JP 2022529996A5 JP 2021562350 A JP2021562350 A JP 2021562350A JP 2021562350 A JP2021562350 A JP 2021562350A JP 2022529996 A5 JP2022529996 A5 JP 2022529996A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pvp
- antibody
- composition
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837647P | 2019-04-23 | 2019-04-23 | |
| US62/837,647 | 2019-04-23 | ||
| PCT/US2020/029328 WO2020219550A1 (en) | 2019-04-23 | 2020-04-22 | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529996A JP2022529996A (ja) | 2022-06-27 |
| JP2022529996A5 true JP2022529996A5 (enExample) | 2023-05-01 |
| JP7739182B2 JP7739182B2 (ja) | 2025-09-16 |
Family
ID=70614677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562350A Active JP7739182B2 (ja) | 2019-04-23 | 2020-04-22 | 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン（ｐｖｐ）の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12599669B2 (enExample) |
| EP (1) | EP3958840A1 (enExample) |
| JP (1) | JP7739182B2 (enExample) |
| CN (1) | CN113660927A (enExample) |
| AU (1) | AU2020263318B2 (enExample) |
| CA (1) | CA3141857A1 (enExample) |
| MX (1) | MX2021012782A (enExample) |
| WO (1) | WO2020219550A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| CN113660927A (zh) | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
| CA3214867A1 (en) * | 2021-04-09 | 2022-10-13 | Courtney O'DELL | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961955A (en) | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US6992066B2 (en) | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| US20080026068A1 (en) | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| JP4679822B2 (ja) | 2002-03-13 | 2011-05-11 | ノバルティス アーゲー | 医薬微粒子 |
| KR20110097772A (ko) | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| AU2009339292B2 (en) | 2008-12-10 | 2016-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| WO2016014408A1 (en) | 2014-07-21 | 2016-01-28 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
| ES2964713T3 (es) * | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN106511997A (zh) | 2015-09-15 | 2017-03-22 | 上海抗体药物国家工程研究中心有限公司 | 一种稳定的蛋白制剂 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US12103979B2 (en) * | 2017-04-28 | 2024-10-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| MA48461A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CN113660927A (zh) | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
-
2020
- 2020-04-22 CN CN202080026162.6A patent/CN113660927A/zh active Pending
- 2020-04-22 US US17/605,512 patent/US12599669B2/en active Active
- 2020-04-22 JP JP2021562350A patent/JP7739182B2/ja active Active
- 2020-04-22 WO PCT/US2020/029328 patent/WO2020219550A1/en not_active Ceased
- 2020-04-22 CA CA3141857A patent/CA3141857A1/en active Pending
- 2020-04-22 MX MX2021012782A patent/MX2021012782A/es unknown
- 2020-04-22 AU AU2020263318A patent/AU2020263318B2/en active Active
- 2020-04-22 EP EP20724707.3A patent/EP3958840A1/en active Pending
-
2026
- 2026-03-10 US US19/562,671 patent/US20260199478A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114452380B (zh) | Il-17抗体的药物产品和稳定液体组合物 | |
| CN110404066B (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| CN104736175B (zh) | 抗催乳素受体抗体制剂 | |
| TWI911431B (zh) | 抗rsv單株抗體配製物 | |
| TWI375566B (en) | High concentration antibody-containing liquid formulation | |
| JP2020518598A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| TWI904081B (zh) | 治療多發性骨髓瘤的方法 | |
| TW201806617A (zh) | 穩定之液體醫藥調配物 | |
| JP2021521205A5 (enExample) | ||
| JP2023501377A (ja) | 高濃度抗ｃ５抗体配合物 | |
| CN106474470A (zh) | 一种抗il‑17a抗体的组合物 | |
| WO2021249445A1 (zh) | 抗il-17a抗体药物组合物及其用途 | |
| JP2005532395A (ja) | 新規な安定処方 | |
| KR20220140772A (ko) | 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법 | |
| JP7739182B2 (ja) | 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン（ｐｖｐ）の使用 | |
| JP7755766B2 (ja) | 抗ｉｌ－６抗体製剤 | |
| JP2025138745A (ja) | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 | |
| JP2021518348A5 (enExample) | ||
| CN111683681B (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| TW202527983A (zh) | 一種包含特異性結合ｇｐｒｃ５ｄ和ｃｄ３的雙特異性抗體的醫藥組成物 | |
| WO2024022414A1 (zh) | 一种高浓度单克隆抗体制剂及其应用 | |
| JP2022518441A5 (enExample) | ||
| CN113698478B (zh) | 抗α-溶血素的抗体及其稳定制剂 | |
| CN118576542A (zh) | 一种稳定的双特异性抗体组合物 |